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Abstract
Background: Rapamycin, a potent immune modulator, is used to treat transplant rejection and some autoimmune diseases.
Uveitis is a potentially severe inflammatory eye disease, and 2 clinical trials of treating uveitis with rapamycin are under way.
Unexpectedly, recent research has demonstrated that low dose rapamycin enhances the memory T cell population and
function. However, it is unclear how low dose rapamycin influences the immune response in the setting of uveitis.
Design and Methods: B10.RIII mice were immunized to induce experimental autoimmune uveitis (EAU). Ocular
inflammation of control and rapamycin-treated mice was compared based on histological change. ELISPOT and T cell
proliferation assays were performed to assess splenocyte response to ocular antigen. In addition, we examined the effect of
rapamycin on activation-induced cell death (AICD) using the MitoCapture assay and Annexin V staining.
Results: Administration of low dose rapamycin exacerbated EAU, whereas treating mice with high dose rapamycin
attenuated ocular inflammation. The progression of EAU by low dose rapamycin coincided with the increased frequency of
antigen-reactive lymphocytes. Lastly, fewer rapamycin-treated T cells underwent AICD, which might contribute to
exaggerated ocular inflammation and the uveitogenic immune response.
Conclusion: These data reveal a paradoxical role for rapamycin in uveitis in a dose-dependent manner. This study has a
potentially important clinical implication as rapamycin might cause unwanted consequences dependent on dosing and
pharmacokinetics. Thus, more research is needed to further define the mechanism by which low dose rapamycin augments
the immune response.
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Introduction
Rapamycin (Sirolimus) is a macrolide initially discovered in
bacterium Streptomyces Hygroscopicu [1]. Through FK binding
protein 12, rapamycin interacts with mammalian target of
rapamycin (mTOR), a serine/threonine protein kinase critical
for cell metabolism and proliferation [2]. Early studies showed that
rapamycin exerts a potent immunosuppressive effect [1,3]. It
inhibits the lymphocyte response to IL-2, and promotes regulatory
T cell (Treg) development and function [1,3]. As a result,
rapamycin, either alone or in conjunction with other immuno-
suppressants, has become a primary immunomodulatory reagent
for preventing transplant organ rejection. Furthermore, rapamycin
has been employed to treat a number of autoimmune/inflamma-
tory diseases [4–6]. In addition, its anti-proliferative effect makes
rapamycin a promising agent for suppressing tumor growth and
coronary arterial restenosis [7–9]. Thus, rapamycin exerts its
therapeutic impact on a broad range of clinical conditions. Despite
the fact that rapamycin is an immunosuppressant, some patients
treated with this medication develop idiosyncratic interstitial
pneumonitis [10–12]. Moreover, recent studies have demonstrated
that low dose rapamycin treatment enhances memory T cell
development and function in a murine viral infection model [13].
This effect appears to be mediated by mTOR [13], which was
supposedly inhibited by rapamycin. This important finding is
unexpected and bears an important clinical implication. For
instance, low dose rapamycin could be used as an adjuvant to
improve vaccine efficacy and to augment memory response to
infection and cancer therapy. Most autoimmune diseases exhibit a
chronic and relapsing course, which is mediated by effector and
memory lymphocytes. Thus, suboptimal dosing of rapamycin
might exacerbate autoimmune and inflammatory diseases. This
may also explain the rare but severe pulmonary complication of
rapamycin in some patients.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36589Autoimmune uveitis is a potentially serious ophthalmologic
disorder characterized by intraocular inflammation. It is com-
monly associated with many systemic diseases characterized by a
dysregulated immune response (e.g. sarcoidosis, ankylosing spon-
dylitis, inflammatory bowel disease). T lymphocytes play an
important role in the pathogenesis of many forms of uveitis by
recognizing antigen and orchestrating the immune response
[13,14]. Recently, 2 clinical trials of intraocular rapamycin
treatment for active uveitis (NCT00908466 and NCT00876434)
were begun. In light of the recent ‘‘paradoxical’’ effect of low dose
rapamycin on T cells, a pre-clinical study is critically needed to
assess the impact of low dose rapamycin on the outcome of uveitis.
Such study could provide valuable information on the dosing of
rapamycin for treating uveitis and other immune-related diseases.
Moreover, it will advance our knowledge of the multifaceted
effects of rapamycin on T cell-mediated immune responses.
In this study, we have demonstrated that administration of low
dose rapamycin exacerbated and prolonged experimental auto-
immune uveitis (EAU), whereas treating mice with a high dose of
rapamycin attenuated ocular inflammation. In addition, the
treatment with low dose rapamycin expanded the peripheral
antigen-reactive-T cell population. Furthermore, rapamycin
treatment reduced activation-induced cell death in the lympho-
cytes. Thus, these findings suggest that low dose rapamycin
amplifies and prolongs the T cell response, thereby leading to
more severe uveitis. Although the mechanism by which low dose
rapamycin augments inflammation remains to be fully defined, the
significance of this study is apparent. Rapamycin therapy might
cause unwanted consequences due to the dosing regimen and
individual pharmacokinetic variations.
Materials and Methods
Mice
Six-week-old female B10.RIII mice (Jackson Laboratory, Bar
Harbor, ME) were used for the experiments. The animal
experimental protocols have been approved by the institutional
animal care and use committee at Oregon Health & Science
University (IACUC number ISO1307).
Experimental autoimmune uveitis
EAU was induced in B10.RIII mice by subcutaneous immuni-
zation (near the base of the tail) with 50 mg interphotoreceptor
retinoid-binding protein peptide 161–180 (IRBP161–180) (Ser-Gly-
Ile-Pro-Tyr-Ile-Ile-Ser-Tyr-Leu-His-Pro-Gly-Asn-Thr-Ile-Leu-
His-Val-Asp) (AnaSpec, Fremont, CA) in 200 ml complete
Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO). On days 14
and 21 after immunization, the eyes were harvested for histology
and real time-PCR.
Histology
For histological evaluation, the eyes were fixed in 3%
paraformaldehyde. Then, the tissues were embedded in paraffin,
sectioned, and stained with hematoxylin and eosin (H&E). Ocular
inflammation was assessed by light microscopy, and the severity of
EAU was graded on a four-point scale based on inflammatory cell
infiltration, retinal folding and destruction [15].
Real time-PCR and Mouse Apoptosis PCRarray
Total RNA from whole eye tissue was isolated with RNAeasy
Mini Kit (Qiagen, Valencia, CA). First-strand cDNA synthesis was
accomplished with oligo (dT)-primed Omniscript reverse tran-
scriptase kit (Qiagen). Gene-specific cDNA was amplified by PCR
using mouse specific primer pairs (IFN-c sense: 59-GCT TTG
CAG CTC TTC CTC AT-39 and IFN-c anti-sense: 59-GTC
ACC ATC CTT TTG CCA GT-39; IL-17A sense: 59-GTG GCG
GCT ACA GTG AAG GCA-39, and IL-17A antisense: 59-GAC
AAT CGA GGC CAC GCA GGT-39; HIF-a1 sense: 59-TCC
ATG TGA CCA TGA GGA AA-39 and HIF-a1 anti-sense: 59-
CTT CCA CGT TGC TGA CTT GA-39; VEGF sense: 59-AGC
ACA GCA GAT GTG AAT GC-39 and VEGF anti-sense: 59-
AAT GCT TTC TCC GCT CTG AA-39; Foxp3 sense: 59-CCC
CTA GTT CCA ACC TAG CC-39, and Foxp3 antisense: 59-
TAC CAA GGC AGG CTC TTC AT-39; IL-10 sense: 59-CCA
AGC CTT ATC GGA AAT GA-39, and IL-10 antisense: 59-TTT
TCA CAG GGG AGA AAT CG-39; TGF-b1 sense: 59-TGG
AGC AAC ATG TGG AAC TC-39, and TGF-b1 antisense: 59-
AGC CCT GTA TTC CGT CTC CT-39; b-actin sense, 59-ATG
CCA ACA CAG TGC TGT CT-39, and b-actin antisense, 59-
AAG CAC TTG CGG TGC ACG AT- 39). The real-time PCR
was performed using a RT
2 Realtime PCR Master mix
(SABiosciences, Valencia, CA), and running for 40 cycles at
95uC for 15 sec and 55uC for 40 sec. The mRNA levels of
investigated genes in each sample were normalized to b-actin
mRNA and quantified using a formula 2
(2DDCt). The result was
expressed as fold change in the groups treated with rapamycin
compared to control EAU.
RNA from cultured DO11.10 splenocytes was isolated to detect
the effect of rapamycin on apoptosis-related gene transcription.
Mouse Apoptosis real-time PCR Array was performed indepen-
dently 3 times according to the manufacturer’s protocol (SABios-
ciences), and GEArrayH Expression Analysis Suite software was
used for data extraction and analysis.
Cell culture, isolation, and stimulation
The spleens were harvested from B10.RIII or DO11.10 mice,
and single cell suspension was prepared by passing the tissue
through a 70 mm cell strainer (BD Biosciences, Mountain View,
CA). Red blood cells (RBC) were lysed with 16RBC lysis buffer
(Sigma, St Louis, MO) at room temperature for 5 min. The spleen
cell suspension was washed with RPMI 1640, and then cultured in
RPMI 1640 with 10% fetal bovine serum (FBS) in an atmosphere
of 95% air and 5% CO2 at 37uC with 4 mg/ml IRBP161–180
peptide for 72 hours.
Flow cytometry
B10.RIII or DO11.10 splenocytes were suspended in phosphate
buffered saline (PBS) containing 2% FBS. Anti-CD4, anti-CD8,
anti-CD44, and anti-CD62L antibodies conjugated with different
fluorescent colors (eBioscience, San Diego, CA) were used to label
these cell surface markers for 60 minute on ice. For Foxp3
staining, the cells were fixed and permeabilized overnight with 16
fixation/permeabilization solution (eBioscience) at 4uC. Then
these cells were stained intracellularly with monoclonal antibody
against Foxp3 (eBioscience) for 1 hour at 4uC. Data acquisition
was performed on a FACSCalibur flow cytometer, and data were
analyzed using CellQuest software. To assess apoptosis, the cells
were incubated with Annexin V (eBioscience) and analyzed by
flow cytometry.
T cell proliferation assay
T cell proliferation responses were assessed by plating 5610
5/
200 ml splenocytes from IRBP161–180-immunized B10.RIII mice in
triplicate into a 96-well flat-bottom tissue culture plate. IRBP161–
180 (0.4 mg/200 ml) or media control were added in a volume of
10 ml/well. Cultures were incubated for 72 h at 37uCi n7 %C O 2.
Wells were pulsed for the final 18 h with 0.5 mCi per well
[
3H]thymidine. The cells were harvested onto glass fiber filters,
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3H]thymidine uptake was measured using a liquid scintilla-
tion counter (1205 Betaplate:Wallac, Turku, Finland). Stimulation
index was calculated by dividing the cmp of sample well by the
blank well.
ELISPOT assay and ELISA
The production of interferon (IFN)-c and interleukin (IL)-17
was quantitated by the ELISPOT assay. Isolated cells were washed
once and seeded at a density of 3610
5 cells per well in triplicate
into 96-well sterile 0.45 mm MultiScreen-HA filter plates (Milli-
pore, Billerica, MA) coated with 5 mg/mL anti-IFN-c or anti-IL-
17 monoclonal antibody (eBioscience). These cells were incubated
in the presence or absence of IRBP (4 mg/ml) for 24 hours at 37uC
in 5% CO2. Then the cells were washed, IFN- c- and IL-17-
producing cells were detected as positive spots by addition of a
second biotin-conjugated anti-IFN- c or anti-IL-17 antibody
(eBioscience), followed by streptavidin alkaline phosphatase and 5-
bromo-4-chloro-3-indolyl phosphate toluidine p-nitro blue tetra-
zolium chloride substrate (KPL, Gaithersburg, MD). Spots were
analyzed by an AID Elispot high resolution reader system EliSpot
04 HR (AID Elispot, Strassberg, Germany).
Fifty ml culture media of isolated B10.RIII splenocytes from
various experimental groups were collected for ELISA to measure
the IFN-c, IL-10, and IL-17 levels according to the manufacturer’s
protocols (BioLegend, San Diego, CA).
MitoCapture apoptosis assay
Apoptosis was assessed using the MitoCapture mitochondrial
apoptosis detection kit (Biovision, Mountain View, CA) according
to the manufacturer’s instructions. Splenocytes from DO11.10
were cultured with and without 100 nM rapamycin for 48 hours.
Then, apoptosis was induced by stimulating the cells with
ovalbumin (OVA) for 3 days. Then, these cells were incubated
in MitoCapture solution at 37uC in a 5% CO2 incubator for
20 min. The splenocytes were washed with PBS and analyzed by
confocal microscopy.
Statistics
Data are expressed as the average 6 SEM. For EAU scoring,
median difference between control and experimental groups was
compared using Mann-Whitney U test. Other statistical probabil-
ities were evaluated by Student’s t test or ANOVA, with a value of
p,0.05 considered significant.
Results
Exacerbation of experimental autoimmune uveitis by low
dose but not high dose rapamycin
To assess the effect of rapamycin on EAU, we treated B10.RIII
mice with intraperitoneal injection of 1.5 or 7.5 mg rapamycin
daily after IRBP161–180 sensitization. On day 21, EAU was scored
based upon inflammatory cell infiltration, vasculitis, retinal
folding, and destruction. Compared to control EAU, the daily
administration of 1.5 mg rapamycin significantly augmented the
severity of EAU, whereas the treatment with 7.5 mg rapamycin
virtually inhibited IRBP161–180-induced uveitis (P,0.05) (Fig. 1A).
As illustrated in Fig. 1B, the mice in the low dose rapamycin-
treated group consistently exhibited more severe retinal destruc-
tion, marked retro-retinal hemorrhage and retinal detachment. In
addition, we examined the expression of mRNA for the
inflammatory cytokines IFN-c and IL-17 in the eyes of these
animals. Total RNA from whole eye was isolated on day 21 after
EAU induction. In line with the histological change, real time-
PCR revealed an increase of Ifn-c and Il-17 transcripts in the
group that received low dose rapamycin compared to the control
group with EAU (Fig. 1C). Hypoxia-inducible factor-1a (HIF-1a)
and vascular endothelial growth factor (VEGF) are implicated in
inflammation and ocular pathology including uveitis [16–20].
Furthermore, recent studies have shown that mTOR signaling
regulates HIF-1a and VEGF expression [21–23]. Low dose
rapamycin can potentially impact on ocular vasculature during
uveitis by altering HIF-1a and VEGF expression. This could
contribute to the retinal hemorrhages and detachment. Thus, we
examined the ocular transcription of HIF-1a and VEGF.
Compared to the control EAU group, real time-PCR showed
that low dose rapamycin treatment increased ocular Hif-1a and
Vegf mRNA expression during EAU (Fig. 1C).
Recently, similar to the observations of others, we reported that
the ocular inflammation peaks at day 14 and subsides at day 21
after IRBP sensitization in our EAU model [24]. Thus, the uveitis
seen in the low dose rapamycin-treated group on day 21 could be
simply due to delayed onset of EAU. To rule out this possibility,
we compared the severity of EAU between the groups with and
without low dose rapamycin on day 14. As shown in Fig. 1D, the
ocular inflammation and retinal injury are comparable in both
control and rapamycin-treated groups. This result indicates that
low dose rapamycin prolongs and exacerbates EAU instead of
merely shifting the kinetics of the ocular immune response.
These findings clearly suggest that low dose rapamycin up-
regulates the immune response in the setting of T cell-mediated
ocular inflammation. The dose-dependent paradoxical effect of
rapamycin on EAU is novel, and it carries potentially significant
implications as low dose rapamycin might cause a detrimental
consequence if the original therapeutic intention is to suppress
immune response.
The effect of low dose rapamycin during the different
stages of EAU development
Recently, Araki et al. reported that treatment of mice with low
dose rapamycin promotes the development of virus-specific T cells
in a lymphocytic choriomeningitis virus infection model [13].
Thus, it is feasible to postulate that low dose rapamycin could
augment the ocular inflammation by up-regulating uveitogenic T
cells. During the first week of antigen encounter, naive T cells are
activated and differentiated to effector lymphocytes. To further
investigate the effect of low dose rapamycin on initial uveitogenic
T cell development, we treated mice intraperitoneally with 1.5 mg
rapamycin for the first 7 days following IRBP inoculation. In
addition, another group of mice received daily rapamycin from
days 10–21 when uveitis becomes histologically apparent. This
enabled us to evaluate the impact of low dose rapamycin on T cell
activation and subsequent T cell response. On day 21 after IRBP
sensitization, the ocular inflammation was mild in the control
EAU group with an average EAU score of 1, whereas the EAU
score increased to 3.5 after the mice were treated with rapamycin
from days 1–21. In addition, the mice receiving rapamycin during
IRBP immunization phase (days 1–7) or after disease onset (days
10–12) developed a mean EAU score of 2.75 and 3.5, respectively
(Fig. 2A). This suggests that low dose rapamycin impacts the
antigen sensitization process and amplifies uveitogenic T cell
activation. To further test if low dose rapamycin enhances the
ocular antigen-specific T cell response, we harvested splenocytes
from these mice on day 21 and re-stimulated the cells with
IRBP161–180 in vitro. The lymphocytes from low dose rapamycin-
treated groups exhibited a higher cell proliferation in response to
IRBP than the control group (Fig. 2B). Among the animals
receiving rapamycin at different stages of EAU development, the
mice displayed the most robust proliferative response to the
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course of the experiment (days 1–21). This indicates that low dose
rapamycin exacerbates EAU by a combined effect on eliciting and
propagating T cell response.
Potential mechanism mediated by low dose rapamycin
Previously, we reported that EAU subsided by day 21 [24].
Here, we found that low dose rapamycin prolonged the course of
uveitis. The continuing ocular inflammation could be due to
suppression of immune regulation or extension of effector T cell
life span. Thus, we went further to investigate the potential
mechanism by which low dose rapamycin augments EAU. Since
recent studies have shown that mTOR is implicated in Foxp3+
Treg differentiation [25–27], we first examined the impact of low
dose rapamycin on the Treg in EAU. On day 21 after IRBP161–180
priming, CD4+CD25+Foxp3+ T cells in the spleen were analyzed
by flow cytometry. As illustrated in Figs. 3A and 3B, there was no
significant change of peripheral Treg population in the EAU mice
treated with and without low dose rapamycin. Furthermore, we
stimulated the splenocytes of these mice with IRBP161–180 in vitro
for 72 hours. IL-10 level in the culture media was determined by
ELISA. Compared to control EAU group, low dose rapamycin did
not significantly alter the production of IL-10 in the animals that
received daily low dose rapamycin in vivo (Fig. 3C). To assess the
impact of rapamycin on ocular Treg cells, Foxp3, IL-10, and
TGF-b expression in the eye was measured by RT-PCR.
Compared to control EAU, ocular transcription of Foxp3, Il-10,
and Tgf-b was attenuated in the low dose rapamycin-treated group
(Fig. 3D). This suggests that low dose rapamycin may inhibit the
ocular trafficking of Treg cells. Alternatively, severe local
inflammation could suppress the expression of Foxp3, IL-10,
and TGF-b in Treg cells.
Several recent studies demonstrated that rapamycin promotes
an antigen-specific T cell response [13,28–30]. Therefore, we
Figure 1. Low dose rapamycin but not high dose rapamycin exacerbates IRBP-induced EAU in B10.RIII mice. The mice received daily
rapamycin (1.5 or 7.5 mg per mouse) via intraperitoneal injection. On day 21, eyes were harvested for histological EAU scoring (A) (Each dot represents
one eye from each mouse in different experimental groups); Representative histology of severe retinal inflammation, folding and damage in low dose
rapamycin-treated EAU (B); Ocular expression of Ifn-c, Il-17, Hif-1a, and Vegf transcripts was measured by quantitative PCR. The mRNA level was
normalized to b-actin, and the relative quantity was further compared between control and low dose rapamycin-treated groups (C) (The data
represent the mean of 6 individual animals in each group). Some mice were euthanized on day 14 after IRBP161–180 inoculation, and ocular
inflammation was compared histologically between control EAU and rapamycin-treated groups (D) (Filled arrow heads: retinal folding; Open arrow
heads: peri-retinal hemorrhage) (Representative histology image of 4 mice in each experimental group).
doi:10.1371/journal.pone.0036589.g001
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population, thereby contributing to the exacerbation of EAU. To
test this hypothesis, we compared the frequency of peripheral
IRBP-reactive lymphocytes between control EAU and in groups
treated with 1.5 mg rapamycin from days 1–21. On day 21 after
EAU induction, splenic lymphocytes were stimulated with
IRBP161–180 in vitro, and the number of IFN-c- and IL-17-
producing cells was analyzed by ELISPOT assay. Compared to
the control EAU group, low dose rapamycin administration
resulted in a significant increase of the relative number of
lymphocytes that produced IFN-c in specific response to
IRBP161–180 (Fig. 4A). However, there was no marked change of
IL-17-producing cells between control and rapamycin-treated
groups (Fig. 4B). We also measured secreted IFN-c and IL-17 in
the culture media. Consistent with the ELISPOT result, ELISA
showed that low dose rapamycin treatment significantly increased
IFN-c but not IL-17 production (Figs. 4C and 4D). This suggests
that low dose rapamycin does not enhance peripheral Th17
differentiation in this model. During ocular inflammation, both
activated Th1 and Th17 cells traffic to and concentrate in the eye.
This could explain the increase of ocular IFN-c and IL-17
transcription in the rapamycin-treated group (Fig. 1C). Although
the induction of EAU is largely elicited by CD4+ T cells, IRBP161–
180 has been shown to induce a CD8+ T cell response [31].
Recently, several studies have demonstrated that low-dose
rapamycin up-regulates CD8+ T cells [13,30]. Therefore, we
investigated if low dose rapamycin could increase activated CD8+
T cells, thereby resulting in exaggerated ocular inflammation. On
day 21 after IRBP161–180 priming, T cell activation markers CD44
and CD62L of splenic CD8+ lymphocytes were analyzed by flow
cytometry in the mice treated with and without rapamycin. As
illustrated in Figs. 5A and 5B, low dose rapamycin did not
significantly increase the number of CD8+CD44+CD62L2
population. To further examine the impact of low dose rapamycin
on CD8+ cell function, we investigated if depletion of CD8+ T
cells attenuated rapamycin-enhanced EAU. Two hundred mg anti-
mouse CD8 monoclonal antibody (Clone 2.43) (BioXcell,
Lebanon, NH) was administered intraperitoneally on days 1 and
8 upon the induction of EAU. On day 21, ocular inflammation
was assessed by intravital microscopy. Compared to the control
Figure 2. Treatment of low dose rapamycin during IRBP sensitization subsequently causes severe EAU. Rapamycin (1.5 mg per mouse)
was administered intraperitoneally during IRBP161–180 sensitization (days 0–7) or after EAU onset (days 10–21) after IRBP161–180 immunization. On day
21, the eyes were harvested for histological evaluation and EAU scoring (A) (Each dot represents one eye from each mouse in different experimental
groups); T cell proliferation assay of the lymphocytes from control and rapamycin-treated mice in response to 72-hour in vitro IRBP161–180 stimulation
(The data represent the mean of 6 individual animals in each group; * p,0.05).
doi:10.1371/journal.pone.0036589.g002
Low Dose Rapamycin Exacerbates Uveitis
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36589EAU group, low dose rapamycin treatment exacerbated ocular
inflammation and retinal damage (Fig. 5C). However, anti-CD8
monoclonal antibody significantly reduced the severity of EAU in
rapamycin-treated mice (Fig. 5C). This suggests that CD8+ T cells
contribute to low dose rapamycin-enhanced ocular immune
response, even though low dose rapamycin does not increase the
percentage of CD8 cells in the spleen.
When peripheral T cells are activated by a specific antigen, they
rapidly enter clonal expansion. Then, a majority of T cells
undergo activation-induced cell death (AICD), a critical process
for containing the immune response [32–35]. Deletion of the
apoptotic molecules regulating AICD leads to exaggerated
inflammation [36,37]. A recent study showed that pre-treatment
with rapamycin inhibits AICD in the epithelial cells [38]. In light
of these reports, we investigated the effect of low dose rapamycin
on AICD in antigen-specific T cells. In order to conveniently
obtain an adequate amount of antigen-specific T cells, we
harvested splenocytes from DO11.10 mice whose transgenic T
cell receptor specifically recognizes OVA. DO11.10 splenocytes
were incubated with OVA for 72 hours, and some DO11.10
lymphocytes were treated with 100 nM rapamycin 48 hours prior
to OVA stimulation. Cell apoptosis was first assessed using a
MitoCapture Detection Kit (BioVision). Disruption of mitochon-
drial membrane potential is an early event of programmed cell
death. In healthy cells, MitoCapture compound aggregates in the
mitochondria to produce bright red fluorescence. Alteration of
mitochondrial membrane potential in apoptotic cells results in the
cytoplasmic accumulation of green fluorescent monomer of the
cationic dye. As illustrated in Fig. 6A, a majority of control cells
exhibited red fluorescence, whereas OVA stimulation markedly
increased green fluorescent apoptotic cells. Conversely, fewer
apoptotic cells were detected in the group pretreated with low dose
rapamycin. Then, we employed mouse apoptosis real-time PCR
array to probe the transcriptional changes of apoptosis-related
genes at 24 hours after OVA stimulation. As shown in Fig. 6B,
100 nM rapamycin augmented the transcription of Bcl2, Bcl2l10,
Figure 3. Low dose rapamycin treatment does not affect peripheral CD4+CD25+Foxp3+ Treg cells but attenuates ocular
transcription of Foxp3, IL-10, and TGF-b. EAU and daily treatment of rapamycin (1.5 mg/mouse) are described previously. On day 21, the spleens
were harvested, and peripheral Treg cells were assessed by flow cytometry for CD4, CD25, and Foxp3 staining. The percentage and total number of
CD4+CD25+Foxp3+ Treg cells were compared between control EAU and low dose rapamycin-treated groups (A and B). The harvested splenocytes
(2.5610
6/ml) were further stimulated with IRBP161–180 (4 mg/ml) in vitro for 72 hours. The cell culture media were collected for ELISA of IL-10 (C). In
addition, the eyes were harvested, and ocular total RNA was isolated for real time-PCR analysis of Foxp3, IL-10, and TGF-b expression. The level of
investigated mRNA was normalized to b-actin, and the relative quantity was further compared with EAU group without low dose rapamycin
treatment (All the data represent the mean of 6 animals per group).
doi:10.1371/journal.pone.0036589.g003
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compared to the control group. The up-regulation of these anti-
apoptotic genes coincided with less apoptosis in rapamycin-treated
cells (Fig. 6A).
In light of above finding, we asked if low dose rapamycin
affected AICD in the EAU model. Thus, B10.RIII mice were
immunized with IRBP161–180 on day 1, and received intraperito-
neal injection of 1.5 mg rapamycin daily. On day 21, the
splenocyte were harvested and stimulated with anti-CD3 and
CD28 antibodies in vitro for 3 days. We used Annexin V staining to
specifically examine the apoptosis of CD4+CD44+ T cells.
Compared to the control group, activation of T cells by anti-
CD3 and anti-CD28 antibodies increased CD4+Annexin V+
lymphocytes (Fig. 7). However, less apoptosis of activated CD4+ T
cells was observed in the groups treated with low dose rapamycin
in vivo (Fig. 7). We also examined apoptotic CD8+ cells in the
splenocytes stimulated with anti-CD3 and CD28 antibodies. In vivo
low dose rapamycin treatment resulted in a slight reduction of
apoptosis in activated CD8+ cells, but did not reach a statistical
difference as compared to the control group without rapamycin
treatment (data not shown). Thus, these data suggest that low dose
rapamycin reduces AICD within the responding CD4+ T cell
population resulting in a greater number of activated T cells
contributing to the autoimmune response.
Discussion
Generally, B10.RIII mice develop significant EAU after they
are immunized with 100 mg IRBP161–180 along with pertussis
toxin. In this study, to better delineate the difference of ocular
inflammation between control and rapamycin-treated groups, we
induced EAU with 50 mg/mouse IRBP161–180 in the absence of
pertussis toxin. With a mild uveitis as a control, we were able to
observe the maximal effect of rapamycin on EAU. Control mice
developed peak EAU on day 14 in response to the lower dose of
IRBP161–180, and the uveitis subsided on day 21. However, we
have demonstrated that low dose rapamycin exacerbated and
prolonged EAU. On day 21, we still observed a robust ocular
inflammatory response and retinal damage. Coinciding with this
finding, we found that daily treatment of low dose rapamycin
Figure 4. Daily low dose rapamycin treatment increases IRBP-reactive T cells in EAU mice. EAU induction and rapamycin treatment are
described previously. On day 21, the splenocytes were harvested, and further stimulated with IRBP161–180 (4 mg/ml) in vitro for 24 hours. Then, the
frequency of IFN-c and IL-17-producing cells was measured by ELISPOT (A and B). In addition, the harvested splenocytes (2.5610
6/ml) were further
stimulated with IRBP161–180 (4 mg/ml) in vitro. The cell culture media were collected for ELISA of IFN-c (C) and IL-17 (D) (All the data represent the
mean of 5–7 animals per group; * p,0.05).
doi:10.1371/journal.pone.0036589.g004
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EAU. In our unpublished study, we also found that daily treatment
of SJL mice with low dose rapamycin consistently augmented
PLP178–191-induced experimental autoimmune encephalomyelitis.
This further validated the effect of low dose rapamycin in an
autoimmune response in a different disease setting. To our
knowledge, this is the first study showing that low dose rapamycin
enhances the autoimmune response in the setting of uveitis. The
significance of this observation is twofold.
First, rapamycin is a potent immunosuppressant clinically used
to treat transplant rejection and some autoimmune diseases. In
light of this finding, suboptimal dosing of rapamycin could exert
an immunological effect that is opposite to the desired therapeutic
intention. For instance, graft rejection and inflammatory responses
may be augmented if an inadequate dose of rapamycin is given to
patients. In addition, it is well documented that genetic variations,
pharmacokinetics, drug interaction and poor treatment compli-
ance can all affect the serum level of rapamycin [39,40]. Many
patients with organ transplantation or autoimmune diseases
commonly receive multiple medications, which can accelerate
rapamycin metabolism. Thus, this experiment underscores the
need to monitor the pharmacokinetics of rapamycin to ensure the
intended therapeutic outcome. In the current clinical trial, it is
worth noting that the uveitis patients receive rapamycin via local
injection. The local application of rapamycin may achieve better
therapeutic concentration in the eye and avoid hepatic biotrans-
formation. Therefore, it would be interesting to compare the
efficacy and safety profile between local and systemic therapies of
rapamycin in uveitis.
In addition to the potential clinical significance, this study is
immunologically intriguing. Although rapamycin is a well
documented immune suppressant, we now report that low dose
rapamycin can actually exacerbate autoimmune uveitis. This
observation is paradoxical to the known effect of rapamycin.
However, this finding is in keeping with recent publications
suggesting this unexpected impact of low does rapamycin. A
number of reports showed the development of interstitial
pneumonitis in the absence of infection as well as chronic
inflammation-related anemia after rapamycin treatment
[11,12,41,42]. Araki et al. have demonstrated that rapamycin
promotes virus-specific memory CD8+ T cell immunity in both
murine and macaque models [13]. In this study, we found that
depletion of CD8+ cells reduced rapamycin-enhanced EAU
(Fig. 5C). This suggests that CD8+ lymphocytes contribute to
low dose rapamycin-augmented autoimmune response in EAU. In
addition, Ford and colleagues report an enhancement of antigen-
specific T cell response by rapamycin in the setting of Listeria
monocytogenes infection [30]. Consistent with this finding, rapamycin
Figure 5. Low dose rapamycin treatment does not affect the number of peripheral activated CD8+ cells. However, anti-CD8 antibody
attenuates rapamycin-enhanced EAU. EAU and daily treatment of rapamycin (1.5 mg/mouse) are described previously. On day 21, the spleens were
harvested, and activated CD8+ cells were assessed by flow cytometry for the surface expression of CD44 and CD62L. The percentage and total
number of CD8+CD44+CD62L2 cells were compared between control EAU and low dose rapamycin-treated groups (A and B) (The data represent the
mean of 5–7 animals per group). Some B10.RIII mice received 200 mg of anti-CD8 antibody intraperitoneally on days 1 and 8 to deplete peripheral
CD8+ cells. On day 21, EAU was evaluated by histology (C) (Representative histology image of 3–4 mice in each experimental group).
doi:10.1371/journal.pone.0036589.g005
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by bacteria [43,44]. Thus, low dose rapamycin could also augment
autoantigen-driven inflammation. It is well documented that IL-12
promotes the development of Th1 cells, whereas IL-23 plays a
critical role in Th17 differentiation. Here, we showed that low
dose rapamycin augmented IFN-c- but not IL-17-producing cells
(Fig. 4) in the context of EAU. It is unclear if low dose rapamycin
treatment skews Th1 differentiation, or it is a phenomenon related
to this specific model since IRBP-induced EAU displays a strong
Th1 response [45]. Thus, further study is needed.
Recent research in a lymphocytic choriomeningitis virus model
has demonstrated that rapamycin treatment during the early T cell
expansion phase increases the population of memory T lympho-
cytes, whereas rapamycin enhances the function of memory cells
when they enter the contraction stage [13,46]. In this study, we
found that treating mice with low dose rapamycin during antigen
sensitization (days 0–7) led to a severe and sustained EAU.
Furthermore, the exacerbation of EAU by low dose rapamycin
coincided with increased frequency of the T cells that specifically
respond to IRBP. This suggests that low dose rapamycin may
augment the T cell response to antigen priming, enhance effector
T cell function and contribute to long-term survival. Despite the
problematic effect of low dose rapamycin within the setting of
autoimmunity, the effect of rapamycin on memory T cells could be
beneficial to improve the long-term immune memory for host
defense. Whether rapamycin might be used as an effective
adjuvant to boost the efficacy of vaccination and immunotherapy
against infections or cancers remains to be tested.
Presently, the molecular mechanism by which low dose
rapamycin enhances T cell response remains to be fully elucidated.
It is well documented that rapamycin inhibits mTOR through the
interaction with FK506 binding protein 12 [2]. mTOR is a serine/
threonine kinase that plays an important role in regulating the
cellular response to external and nutritional cues [46–49]. Using
RNA-interference knockdown technique, Araki et al. have shown
that rapamycin facilitates memory T cell differentiation via
mTOR complex 1 pathway [13]. It is thought that metabolic
status exerts a pivotal impact on T cell programming. High
metabolic state drives effector T cell development, whereas low
metabolic cue is in favor of memory T cell differentiation [50].
This notion is further supported by a recent study showing that
suppression of fatty acid metabolism promotes a memory T cell
response [51]. Thus, inhibition of mTOR by low dose rapamycin
may reset the metabolic switch, leading to more memory T cell
Figure 6. Pre-treatment of low dose rapamycin attenuates activation-induced cell death of DO11.10 CD4+ T cells. Splenocytes were
harvested from DO11.10 mice. They were pre-treated with or without 100 nM rapamycin for 48 hours. Then, these cells were cultured in the presence
of OVA for additional 72 hours. Apoptosis of DO11.10 splenocytes was detected by MitoCapture assay (Representative image of the cells from 3
individual mice in each group) (A). In addition, 24 hours after OVA stimulation, total RNA was collected from cultured DO11.10 splenocytes, and
Mouse Apoptosis PCRarray was performed to compare the change of anti-apoptotic gene expression between control and rapamycin treated cells
(The data represent the mean of 3 independent experiments with total 3 mice in each group).
doi:10.1371/journal.pone.0036589.g006
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activity. Yet it displays a potent T cell suppression effect. Thus,
another mechanism is likely to be involved in the response that
develops following low dose rapamycin. After antigen activation, T
cells expand rapidly. During the subsequent contraction phase, a
majority of effector T cells undergo apoptosis, and a few surviving
lymphocytes develop into the memory lineage. A recent study
showed that long-term rapamycin treatment can improve mouse
longevity [52], suggesting that rapamycin may regulate the
apoptosis process. In fact, our study showed that pre-treatment
of rapamycin attenuated AICD and apoptotic molecule expression
in antigen-activated lymphocytes. In the setting of autoimmune
diseases, waves of naı ¨ve T cells will gain an access to antigens
during different stages of the inflammatory process. Rapamycin-
primed naı ¨ve lymphocytes could resist AICD after encountering
an antigen. Thus, low dose rapamycin may prolong the life span of
effector lymphocytes and facilitate the generation of memory T
cells by its potential anti-apoptotic effect. However, we believe that
inhibition of AICD is only a part of the mechanism by which low
dose rapamycin augments the immune response. A recent study
demonstrated that autophagy enhances immune response in part
by releasing ATP to recruit dendritic cells, CD4+ and CD8+
lymphocytes [53]. Since rapamycin inhibits mTOR, a negative
regulator of autophagy [54,55], low dose rapamycin could
exacerbate EAU by augmenting autophagy [56]. Although
treatment with rapamycin during different stages of EAU
development resulted in a similar outcome of ocular inflammation
(Fig. 2A), our study showed that peripheral T cells from the mice
treated with low dose rapamycin from day 1 to day 21 exhibited
an enhanced IFN-c response to ocular antigen re-stimulation
(Fig. 4). This suggests that low dose rapamycin during other phases
of EAU development may augment ocular inflammation through
different immune cells and/or mediators.
In summary, our study reveals that low dose rapamycin
enhances the autoimmune response in the setting of uveitis. This
finding is clinically important as it raises the concern of an
unintended consequence from low dose rapamycin and under-
scores the need to validate dosing and pharmacokinetics during
rapamycin therapy. In addition, these data suggest that rapamycin
may be used to help enhance a developing immune response, a
premise requiring additional investigation in different model
systems.
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